MAP4K1

Across TCGA pan-cancer cohorts, MAP4K1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated MAP4K1 data layer compared with 22 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MAP4K1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAP4K1 expression acts as an unfavorable survival marker, although some lineages such as LUSC and BLCA show a favorable association.

OV, HNSC, and LIHC are the cancer types where MAP4K1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.022	0.846	<.001	36	view →
HNSC	OS	Median	III,IV	0.457	0.752	.003	25	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
PAAD	DFS	Median	All	0.112	0.504	.025	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	DFS	Median	All	1.000	0.752	.040	4	view →
SKCM	DFS	Median	All	0.361	0.641	.045	2	view →
BLCA	OS	Median	III,IV	1.000	0.533	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MAP4K1–OV (OS)

Open the OV breakdown →